A patient among the first to be given a pioneering cancer treatment which uses his own immune system to fight it says his disease is 'on the run'. This type of cancer develops from abnormal blood cells and affects around 4,800 people in the UK each year. NICE - which provides guidance for the NHS - also recommends CAR-T therapy for adults with diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma. Only seven hospitals in England offer the CAR-T treatment for adults with large B-cell lymphoma, while nine offer it to children with leukaemia. CAR-T treatment is listed as costing more than £280,000 per patient, but the NHS gets it cheaper through a deal with US firm Gilead Sciences.

Source: Daily Mail June 21, 2019 10:07 UTC